Cell line · CVCL_1267
Papers67
1 to 20 of 67
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| The role of autoproteolysis and mitoribosomal proteins in the regulation of the mitochondrial LACTB tumor suppressor. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HSPA8 globally modulates transcriptome profile and PI3K/AKT signaling pathway to facilitate malignant progression phenotypes of triple-negative breast cancer. | Sci Prog | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TSPYL5 Promotes Triple-Negative Breast Cancer Metastasis by Antagonizing USP10-Mediated PTEN Stabilization to Unleash a ZEB1-Dependent EMT Program. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC. | Cancer Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Hypoxia Induces Immunosuppression by Silencing STING in Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| LINC01235 Is an Upstream Regulator of the NFIB Gene and the Notch Pathway in Triple-Negative Breast Cancer. | Mol Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkers. | Cancer Lett | 2025 | Cellosaurus cites it | PubMed | |
| Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. | Front Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors. | Mol Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Discovery, Validation and Mechanistic Study of XPO1 Inhibition in the Treatment of Triple-Negative Breast Cancer. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. | Sci Adv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Protein kinase D drives the secretion of invasion mediators in triple-negative breast cancer cell lines. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Improved approaches to channel capacity estimation discover compromised GPCR signaling in diverse cancer cells. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Disruption of CDK7 signaling leads to catastrophic chromosomal instability coupled with a loss of condensin-mediated chromatin compaction. | J Biol Chem | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1267/papers